ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Beyang Therapeutics raised $30 million in Series A funding. The financing will support the company's research and development efforts. The round marks a significant early-stage investment in the biotech sector.
Tap to vote and see what everyone thinks.
Summary by ByteBrief